Zhang YF, Xu R, Luo J, Ma Y, Xiao G, Liu Y. Identification of Mannose-Capped-Arabinomannan 101-mer as a Potential Influenza Virus Vaccine Adjuvant. Adv Sci (Weinh). 2026 Feb 3:e19843
Many natural bacterial components as adjuvants can activate the host immune system, but the excessive toxicity and structure-identification challenge limit their applications and structure-activity relationship studies. Herein, we report the role of a series of chemically synthesized mannose-capped arabinomannan motifs from Mycobacterium tuberculosis cell wall, including 18-mer, 19-mer, 27-mer, and 101-mer in regulating host immunity. As an influenza vaccine adjuvant, 101-mer induced significantly enhanced anti-influenza antibody response and immune protection compared with other arabinomannan motifs. 101-mer elicited robust immunoenhancement while exhibiting a favorable tolerability profile, as it did not trigger any observable physiological toxicity or inflammatory reactions in various organs. Mechanistically, we found 101-mer may serve as a Dectin-2 agonist to activate host immunity through Syk/NF-κB signaling. This study provided a new oligosaccharide candidate that can satisfy the required "efficacy-safety" balance for clinical adjuvant development.
See Also:
Latest articles in those days:
- Imported case of avian influenza A(H9N2) virus infection in a patient with miliary tuberculosis, Italy, March 2026 24 hours ago
- Characterization and Genetic Evolution of H6N2 Subtype AIV Isolates from Aquatic Birds 1 days ago
- Evaluation of experiences in mass depopulation of upland gamebirds in response to HPAI H5N1 outbreaks in North America: a mixed-methods study 1 days ago
- Highly Pathogenic Avian Influenza A(H5N1) Virus RNA in Bovine Semen, California, USA, 2024 2 days ago
- Rapid expansion of genotype D1.1A(H5N1) influenza viruses in wild birds across North America during the 2024 migratory season 2 days ago
[Go Top] [Close Window]


